Ats 2013 abstracts online dating
Ats 2013 abstracts online dating - lauffener bote online dating
Secondary endpoints included transition dyspnea index (TDI) score, trough FEV, forced vital capacity (FVC) and safety and tolerability,.About Ultibro Breezhaler Ultibro Breezhaler (indacaterol/glycopyrronium bromide) is a novel, once-daily dual bronchodilator approved as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.
Ultibro Breezhaler was developed and previously known as QVA149.
These sessions summarise the latest clinical advances, research, guidelines, and UEG Week abstracts in each area in 2013.
If you have concentrated on one area in the meeting, this is the perfect opportunity to catch up on another subject which interests you!
It has been running since 1992 and now attracts more than 14,000 people from across the world.
It features the latest advances in clinical management, the best research in GI and liver disease and includes several different kinds of symposia and fora, where cutting edge gastroenterology and hepatology is being discussed.
(indacaterol/glycopyrronium) 110/50 mcg compared to tiotropium 18 mcg plus formoterol 12 mcg in terms of health-related quality of life (HRQo L) outcomes in moderate-to-severe chronic obstructive pulmonary disease (COPD) patients at week 26,.
Positive results from QUANTIFY are part of 16 Novartis respiratory abstracts being presented at the American Thoracic Society (ATS) International Conference, May 16-21, 2014 in San Diego, CA, USA.In the QUANTIFY study, which included over 900 COPD patients, once-daily Ultibro Breezhaler showed superior improvements in lung function (trough FEV) at 26 weeks compared to once-daily tiotropium plus twice-daily formoterol in moderate-to-severe COPD patients.Additionally, patients taking Ultibro Breezhaler were more likely to demonstrate a clinically meaningful improvement in shortness of breath and health-related quality of life (per protocol set) at 26 weeks compared to tiotropium plus formoterol.The safety and tolerability of Ultibro Breezhaler was comparable to the other treatment arm in the study,."These positive results from QUANTIFY demonstrate that once-daily Ultibro Breezhaler can provide better symptom control versus a combination of two individual treatments, tiotropium plus formoterol," said Tim Wright, Global Head of Development, Novartis Pharmaceuticals."More patients on Ultibro Breezhaler had a meaningful improvement in health-related quality of life demonstrating superiority of our LABA/LAMA vs tiotropium plus formoterol." COPD affects an estimated 210 million people worldwide and is projected to be the third leading cause of death by 2020.